A cross-sectional study has shown wide disparity in virologic-failure rates across countries, primarily reflecting different prevalences of drug-resistance mutations.
Although access to antiretroviral therapy (ART) in resource-limited settings has improved, poor treatment outcomes and the emergence and transmission of drug-resistant viruses remain important challenges that could undermine programmatic successes. The WHO public health approach (i.e., standardization of ART services through use of clinical/immunological criteria only for ART initiation or switch, limited access to virologic monitoring, and use of low–genetic barrier drugs) may favor the rapid emergence, spread, and transmission of resistant viruses.
In a recent cross-sectional study, researchers evaluated treatment outcomes, including virologic failure and drug resistance, among patients attending ART services in seven resource-limited coun…
Reviewing Authors
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes